publication . Article . Other literature type . 2017

Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP

Ulrich Beuers; Benno Zehnder; Mark J. Kwakkenbos; Adriaan P. IJzerman; Gerard J. P. van Westen; Joanne M. Donkers; Stan F.J. van de Graaf; Stephan Urban; Stephan Urban; Ronald P.J. Oude Elferink;
Open Access English
  • Published: 10 Nov 2017
  • Country: Netherlands
Abstract
<p>The sodium taurocholate co-transporting polypeptide (NTCP, SLC10A1) is the main hepatic transporter of conjugated bile acids, and the entry receptor for hepatitis B virus (HBV) and hepatitis delta virus (HDV). Myrcludex B, a synthetic peptide mimicking the NTCP-binding domain of HBV, effectively blocks HBV and HDV infection. In addition, Myrcludex B inhibits NTCP-mediated bile acid uptake, suggesting that also other NTCP inhibitors could potentially be a novel treatment of HBV/HDV infection. This study aims to identify clinically-applied compounds intervening with NTCP-mediated bile acid transport and HBV/HDV infection. 1280 FDA/EMA-approved drugs were screen...
Persistent Identifiers
Subjects
Medical Subject Headings: digestive systemvirus diseases
free text keywords: Article, Multidisciplinary, Virus, Taurocholic acid, chemistry.chemical_compound, chemistry, Virology, Viral entry, SLC10A1, biology.protein, biology, Hepatitis B, medicine.disease, medicine, Bile acid, medicine.drug_class, Hepatitis B virus, medicine.disease_cause, Organic anion transporter 1, business.industry, business, lcsh:Medicine, lcsh:R, lcsh:Science, lcsh:Q
Funded by
EC| PROLONGBILESIGNALING
Project
PROLONGBILESIGNALING
Improving Metabolism via Prolonged Bile Acid Signalling targeting hepatic bile acid uptake to fight metabolic diseases
  • Funder: European Commission (EC)
  • Project Code: 337479
  • Funding stream: FP7 | SP2 | ERC
Download fromView all 8 versions
NARCIS
Article . 2017
Provider: NARCIS
Scientific Reports
Article . 2017
Provider: Crossref
50 references, page 1 of 4

Dawson, PA, Lan, T, Rao, A. Bile acid transporters. J Lipid Res. 2009; 50: 2340-2357 [OpenAIRE] [PubMed] [DOI]

Yan, H. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and Dvirus. Elife. 2012; 1: e00049 [OpenAIRE] [PubMed] [DOI]

Ni, Y. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. 2014; 146: 1070-1083 [OpenAIRE] [PubMed] [DOI]

Seeger, C, Mason, WS. Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000; 64: 51-68 [OpenAIRE] [PubMed] [DOI]

Alvarado-Mora, MV, Locarnini, S, Rizzetto, M, Pinho, JR. An update on HDV: virology, pathogenesis and treatment. Antivir Ther. 2013; 18: 541-548 [OpenAIRE] [PubMed] [DOI]

Taylor, JM. Virology of hepatitis D virus. Semin Liver Dis. 2012; 32: 195-200 [OpenAIRE] [PubMed] [DOI]

Lempp, FA, Ni, Y, Urban, S. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. Nat Rev Gastroenterol Hepatol. 2016; 13: 580-589 [OpenAIRE] [PubMed] [DOI]

Verrier, ER. Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes. Cell Rep. 2016; 17: 1357-1368 [OpenAIRE] [PubMed] [DOI]

Meier, A, Mehrle, S, Weiss, TS, Mier, W, Urban, S. Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. Hepatology. 2013; 58: 31-42 [OpenAIRE] [PubMed] [DOI]

Schieck, A. Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts. Hepatology. 2013; 58: 43-53 [OpenAIRE] [PubMed] [DOI]

Gripon, P. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA. 2002; 99: 15655-15660 [OpenAIRE] [PubMed] [DOI]

Schulze, A, Schieck, A, Ni, Y, Mier, W, Urban, S. Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J Virol. 2010; 84: 1989-2000 [OpenAIRE] [PubMed] [DOI]

Bogomolov, P. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J Hepatol. 2016; 65: 490-498 [OpenAIRE] [PubMed] [DOI]

Li, W, Urban, S. Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications. J Hepatol. 2016; 64: S32-40 [OpenAIRE] [PubMed] [DOI]

Lutgehetmann, M. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology. 2012; 55: 685-694 [OpenAIRE] [PubMed] [DOI]

50 references, page 1 of 4
Any information missing or wrong?Report an Issue